(Q48910862)

English

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

scientific article published in February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Eduard Vieta

8

0 references

author name string

Marc L M van der Loos

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Paul Mulder

2

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Erwin G Th M Hartong

3

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Marc B J Blom

4

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Anton C Vergouwen

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Martijn S van Noorden

6

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Manuela A Timmermans

7

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Willem A Nolen

9

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

LamLit Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Bipolar Disorders

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

13

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

111-117

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

The long-term natural history of the weekly symptomatic status of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Effectiveness of adjunctive antidepressant treatment for bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Antidepressants in bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00887.X

21 January 2018

Identifiers

10.1111/J.1399-5618.2011.00887.X

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21320258

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48910862&oldid=1522805506"